Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TNK2 | Q07912 | 9/20 | 0.37 |
| ▸ | ADAMTS4 | O75173 | 1/20 | 0.35 |
| ▸ | MAP4K2 | Q12851 | 2/20 | 0.34 |
| ▸ | GRM5 | P41594 | 1/20 | 0.34 |
| ▸ | FPR2 | P25090 | 1/20 | 0.33 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.33 |
| ▸ | BTK | Q06187 | 1/20 | 0.33 |
| ▸ | SYK | P43405 | 1/20 | 0.33 |
| ▸ | ZAP70 | P43403 | 2/20 | 0.33 |
| ▸ | KARS1 | Q15046 | 2/20 | 0.33 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.33 |
| ▸ | TSHR | P16473 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31745561 | 0.83 | TNK2 (0.35) | TNK2ADAMTS4BTK | |
| SCHEMBL31745508 | 0.82 | MAP2K7 (0.42) | BTKSYKZAP70 | |
| SCHEMBL31360346 | 0.81 | BTK (0.38) | GRM5BTKSYK | |
| SCHEMBL31745524 | 0.72 | TNK2 (0.36) | TNK2BTK | |
| SCHEMBL29002666 | 0.71 | PARP1 (0.39) | ADAMTS4GRM5FPR2SCN9ASYK | |
| SCHEMBL31745551 | 0.70 | BTK (0.38) | GRM5BTK | |
| SCHEMBL31745492 | 0.69 | GRM5 (0.36) | ADAMTS4GRM5BTK | |
| SCHEMBL29002670 | 0.68 | MAP2 (0.37) | ADAMTS4GRM5FPR2SCN9ASYK | |
| SCHEMBL25715990 | 0.68 | TNK2 (0.51) | TNK2BTK | |
| SCHEMBL31745504 | 0.67 | BTK (0.34) | TNK2ADAMTS4GRM5BTKSYK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250382297-A1 | INHIBITORS OF FGFR2 AND FGFR3 AND USES THEREOF | INSILICO MEDICINE IP LTD (HK) | 2025-12-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250382297-A1 | INHIBITORS OF FGFR2 AND FGFR3 AND USES THEREOF | FGFR3, FGFR2, FGFR1 | TNK2 452/4885ADAMTS4 1032/4885MAP4K2 606/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.